Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion

NCT07738055 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Potentially Resectable Hepatocellular Carcinoma

Interventions

DRUG: Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks

Sponsor

Tianjin Medical University Cancer Institute and Hospital